Presenters at the recent San Antonio Breast Cancer Symposium (SABCS; December 4–8, 2018) reported the latest findings in breast cancer research. NEJM Journal Watch Oncology and Hematology Editor-in-Chief Dr. William Gradishar was on hand to summarize results of the key studies. For more information on the meeting, please visit the SABCS website, and for access to the abstracts, please visit the abstracts portal.
Adjuvant Trastuzumab Emtansine for HER2-Positive Early Breast Cancer
One of the key presentations at the 2018 SABCS was the randomized, open-label, phase III study of adjuvant trastuzumab plus emtansine by Geyer and colleagues (KATHERINE; abstract GS1-10; N Engl J Med Dec 5 2018; [e-pub]), involving 1486 patients with HER2-positive ea…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)